News

Heparin-Coated Stent Graft Produced High SFA Patency


 

FROM ISET 2012, AN INTERNATIONAL SYMPOSIUM ON ENDOVASCULAR THERAPY

"We can’t wait for patients to become symptomatic or have their ankle-brachial index drop. We have to follow patients closely with duplex ultrasound," after SFA revascularization, Dr. Saxon said.

The VIPER trial was sponsored by W.L. Gore. Dr. Saxon disclosed ties with W.L. Gore, Cook, Lutonix, Concentric Medical, Vascular Resources, Abbott Vascular, and Reva Medical. Dr. Ansel disclosed ties with Abbott Vascular, Boston Scientific, Access Closure, Angioslide, Arsenal Medical, Atheromed, Atrium Medical, Bard, and Biocardia.

Pages

Recommended Reading

Community Hospital Offers Catheter-Directed Pulmonary Thrombolysis
MDedge Cardiology
Virtual Reality Allows Patient-Specific Surgery Simulation
MDedge Cardiology
Stem Cell Therapy Prompts 'Unprecedented' Myocardial Regeneration After MI
MDedge Cardiology
Transcatheter Valve Replacement Takes Center Stage
MDedge Cardiology
CABG Beats Stents for Long-Term Outcomes in High-Risk Patients
MDedge Cardiology
Transaortic Approach Works for TAVI With Sapien
MDedge Cardiology
BLOG: Revolutionizing Ischemic Brain Management, at a Stroke
MDedge Cardiology
Race and Sex Skew Congenital Heart Surgery Outcomes
MDedge Cardiology
Post-MI Stem Cell Therapy Improves Cardiac Function
MDedge Cardiology
Bivalirudin as Safe as Unfractionated Heparin for Pre-PCI Switch
MDedge Cardiology